Методичні вказівки для проведення практичних занять і організації самостійної роботи з навчальної дисципліни «Управління нерухомим майном» (для студентів 4 курсу денної і заочної форм навчання напряму підготовки 6.080101 – Геодезія, картографія та землеустрій).

Table S2. Week-4 simeprevir pharmacokinetic parameters after administration in (a) Panels 1–3 and (b) Panel 4. (DOCX 15 kb

Δ cytokine levels in different groups of patients.

<p>Δ cytokine values, calculated as Hepatic venous value (pg/mL) /Peripheral value (pg/mL), in patients respectively without an established diagnosis of Non-alcoholic Steatohepatitis (NASH) in comparison with NASH patients, patients without and with diabetes mellitus (DM) and patients without and with portal hypertension (PH). IL: interleukin, INFγ: interferonγ, TNFα: tumour necrosis factor α.</p><p># p = 0.02</p><p>* p = 0.01</p><p>Δ cytokine levels in different groups of patients.</p

Significant correlations between IL10/IL17a ratio and clinical features.

<p>IL10/IL17a Significant correlation with the respective correlation coefficient (p<0.05). The peripheral (P)- and hepatic venous (HV)-IL10/IL17 ratios negatively correlated with fasting insulin.</p

Significant correlations between IL6 levels and clinical features.

<p>IL6 level in peripheral blood (P) correlated with the visceral fat amount.</p

Liver histology.

<p>Non-alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) was calculated as the sum of the subscores for steatosis, lobular inflammation and ballooning.</p><p>Liver histology.</p

patients’ main characteristics.

<p>Number (n) or mean value ± standard deviation (SD). BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, WHR: waist-hip ratio, CRP: C-reactive protein, GGT: gamma glutamyl transpeptidase, HDL: high-density lipoprotein, LDL: low-density lipoprotein, HbA1C: haemoglobin A1C, HOMA-IR: homeostasis model assessment of insulin resistance, NASH: Non-alcoholic Steatohepatitis, HVPG: hepatic venous pressure gradient, MAP: mean arterial pressure, CVP: central venous pressure, mPAP: mean pulmonary artery pressure, PCWP: pulmonary capillary wedge pressure, CI: cardiac index, SVRI: systemic vascular resistance index.</p><p>patients’ main characteristics.</p

Significant correlations between M1/M2 ratio and clinical features.

<p>M1/M2 significant correlations with the respective correlation coefficient (p<0.05). The peripheral (P)-M1/M2 ratio positively correlated with steatosis grade and with fasting insulin. The hepatic venous (HV)-M1/M2 ratio positively correlated with fasting insulin.</p

Beneficial Effects of Anti-Interleukin-6 Antibodies on Impaired Gastrointestinal Motility, Inflammation and Increased Colonic Permeability in a Murine Model of Sepsis Are Most Pronounced When Administered in a Preventive Setup - Fig 2

<p><b>Effect of</b><u><b><i>preventive</i></b></u><b>treatment with anti-IL-6 antibodies on sepsis-induced clinical signs of disease 24h (A) and 48h (B) following CLP or sham-surgery, percentage of weight loss at day 1 (C), percentage of gastric emptying (D), geometric center of GI transit (E) and colonic permeability as measured by the <i>Evans blue</i> method (F).</b> Two-way ANOVA followed by One-way ANOVA and SNK <i>post-hoc</i> testing when appropriate, or its non-parametric equivalent for ordinal data; n = 7–10/group for A, B and C; n = 9–12/group for D; *p ≤ 0.05, ***p ≤ 0/001, # significant effect of CLP, § significant effect of anti-IL-6. CDS: clinical disease score; CLP: caecal ligation and puncture; GC: geometric center; %GE: percentage of gastric emptying; GI: gastrointestinal.</p

Cytokine levels in serum (A) and supernatants of homogenized colons (B) measured by CBA, and determined by RT-PCR in colon (C) during the <i>curative</i> set-up (administration of anti-IL-6 antibodies 24h following the CLP- or sham-procedure).

<p>Cytokine levels in serum (A) and supernatants of homogenized colons (B) measured by CBA, and determined by RT-PCR in colon (C) during the <u><i>curative</i></u> set-up (administration of anti-IL-6 antibodies 24h following the CLP- or sham-procedure).</p

Kaplan-Meier survival analysis.

<p>Kaplan-Meier curve displaying survival of sham and CLP-mice treated with anti-IL-6 antibodies or IgG isotype control up until 48h following the CLP-procedure. Log rank test p = 0.011.</p